Rohit Dhall
Credentials | Certified Physician Executive |
---|
| MD |
---|
Title | Department Chairperson |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Neurology, College of Medicine |
---|
Division | Neurology Faculty |
---|
Address | 501 Jack Stephens Drive Mail Slot # 500 Little Rock AR 72205
|
---|
Phone | 501-686-7236 |
---|
ORCID
| 0000-0001-9436-1920 |
---|
vCard | Download vCard |
---|
|
|
|
Overview My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and improving programs delivering care to neurological patients. I direct the division of Neurodegenerative Disorders, and UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Huntington Disease Center of Excellence. I also serve as the Medical Director of the Clinical Trials Innovation Unit at the Translational Research Institute at UAMS.
Biography Chair Department of Neurology
Medical Director, Clinical Trials Innovation Unit
Director, Parkinson Foundation Comprehensive Care Center
Director of CurePSP Center of Care at UAMS
All India Institute of Medical Sciences, New Delhi, India | MBBS (MD) | 12/2000 | Medicine, Surgery | Univ. of Texas at Houston, School of Public Health, Houston, TX | MSPH | 12/2008 | Epidemiology | Univ. of Alabama at Birmingham, Birmingham, AL | Residency training | 07/2007 | Neurology | Univ. of Alabama at Birmingham, Birmingham, AL | Fellowship Training | 07/2009 | Movement Disorders and Deep Brain Stimulation | American Association of Physician Leaders | Certified Physician Executive | 11/2019 | Physician Leadership | Harvard T.H. Chan School of Public Health Executive and Continuing Professional Education, Boston, MA | NA | 02/2024 | Program for Chairs of Clinical Services | Univ. of Texas at Houston, Houston, TX | NA | 06/2003 | Medicine Internship |
2011 - 2021 | Elected by his peers for inclusion in Best Doctors in America®, Best Doctors Inc | 2021 - 2024 | Elected by his peers for inclusion in Top Doctors ® , Castle Connolly | 2021 - 2022 | Outstanding Mentor Award for educating and mentoring Geriatrics fellows , UAMS Institute on Aging | 2023 - 2024 | Red Sash Award for Medical Student Education, Univ. of Arkansas for Medical Sciences |
Teaching Research SAGE-718 (DHALL, ROHIT)May 1, 2024 - Apr 30, 2034 Sage Therapeutics - Pass Through: PAREXEL International LLC A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long-Term Safety and Tolerability of SAGE-718 in Participants with Huntington's Disease (IRB 276546) Role: Principal Investigator |
| PF-CCC (DHALL, ROHIT)Dec 1, 2023 - Nov 30, 2024 Parkinson's Foundation Parkinson’s Foundation CCC Role: Principal Investigator |
| PF-CCC-1260184 (DHALL, ROHIT)Dec 1, 2023 - Nov 30, 2024 Parkinson's Foundation Parkinson’s Foundation CCC Role: Principal Investigator |
| PF-COE-AC (DHALL, ROHIT)Jul 1, 2023 - Nov 30, 2023 Parkinson's Foundation Parkinson’s Foundation Center Bridge Funding Grant Role: Principal Investigator |
| PF-COE-AC-1275661 (DHALL, ROHIT)Jul 1, 2023 - Nov 30, 2023 Parkinson's Foundation Parkinson’s Foundation Center Bridge Funding Grant Role: Principal Investigator |
| IkT (DHALL, ROHIT)Dec 16, 2022 - Dec 15, 2032 Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc. A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673) Role: Principal Investigator |
| IkT-148009-201 (DHALL, ROHIT)Dec 16, 2022 - Dec 15, 2032 Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc. A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673) Role: Principal Investigator |
| PD0053 (DHALL, ROHIT)Sep 13, 2022 - Sep 12, 2032 UCB Biopharma - Pass Through: PAREXEL International LLC A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease (IRB 274317) Role: Principal Investigator |
| C25304 (DHALL, ROHIT)Aug 25, 2022 - Aug 24, 2032 Huntington Study Group Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™) (IRB 274554) Role: Principal Investigator |
| CLR (DHALL, ROHIT)Aug 15, 2022 - Aug 14, 2032 Sun Pharma Advanced Research Company Limited (SPARC) - Pass Through: Labcorp Drug Development Inc. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929) Role: Principal Investigator |
| CLR-18-06 (DHALL, ROHIT)Aug 15, 2022 - Aug 14, 2032 Sun Pharma Advanced Research Company Limited (SPARC) - Pass Through: Labcorp A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929) Role: Principal Investigator |
| C24162 (DHALL, ROHIT)Jul 14, 2022 - Jul 13, 2032 Alexion Pharmaceuticals - Pass Through: PPD Investigator Services, LLC A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis (IRB 273880) Role: Principal Investigator |
| ABP (DHALL, ROHIT)Oct 8, 2021 - Oct 7, 2031 AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548) Role: Principal Investigator |
| ABP-19000 (DHALL, ROHIT)Oct 8, 2021 - Oct 7, 2031 AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548) Role: Principal Investigator |
| CVL (DHALL, ROHIT)Apr 22, 2021 - Jun 17, 2031 Cerevel Therapeutics, LLC - Pass Through: Syneos Health 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509) Role: Principal Investigator |
| CVL-751-PD-004 (DHALL, ROHIT)Apr 22, 2021 - Jun 17, 2031 Cerevel Therapeutics, LLC - Pass Through: Syneos Health 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509) Role: Principal Investigator |
| ND0612 (DHALL, ROHIT)Mar 3, 2021 - Mar 24, 2031 NeuroDerm, Ltd. - Pass Through: Syneos Health A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930) Role: Principal Investigator |
| ND0612-317 (DHALL, ROHIT)Mar 3, 2021 - Mar 24, 2031 NeuroDerm, Ltd. - Pass Through: Syneos Health A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930) Role: Principal Investigator |
| M15-736 (DHALL, ROHIT)Sep 18, 2020 AbbVie Inc No FP attached Role: Principal Investigator |
| CVL-751-PD-001 (DHALL, ROHIT)Sep 10, 2020 - Aug 26, 2030 Cerevel Therapeutics, LLC - Pass Through: Syneos Health A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL) Role: Principal Investigator |
| ALXN1210-MG (DHALL, ROHIT)Sep 9, 2020 Alexion Pharmaceuticals - Pass Through: Syneos Health A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia Gravis (261071) Role: Principal Investigator |
| ALXN1210-MG-306 (DHALL, ROHIT)Sep 9, 2020 Alexion Pharmaceuticals - Pass Through: Syneos Health No FP attached Role: Principal Investigator |
| NLY01-PD-1, (DHALL, ROHIT)Jun 11, 2020 - Jun 10, 2030 Neuraly - Pass Through: Rho, Inc No FP attached Role: Principal Investigator |
| IPX203-B16-03 (DHALL, ROHIT)Dec 9, 2019 - Dec 10, 2029 Syneos Health No FP attached Role: Principal Investigator |
| Study 003 (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024 Global Kinetics Corporation Ltd. No FP attached Role: Principal Investigator |
| Study003 (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024 Global Kinetics Corporation Ltd. Utilization of Target Ranges to Treat Patients with Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled Trial (IRB 250009) Role: Principal Investigator |
| IPX203-B16-02 (DHALL, ROHIT)May 15, 2019 Impax Laboratories, Inc. No FP attached Role: Principal Investigator |
| IRB # 228403 (DHALL, ROHIT)Jan 8, 2019 Cala Health, Inc PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Role: Principal Investigator |
| IRB#228403 (DHALL, ROHIT)Jan 8, 2019 Cala Health, Inc PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Role: Principal Investigator |
| P2B001-003 (DHALL, ROHIT)Aug 16, 2018 - Aug 15, 2028 Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc. No FP attached Role: Principal Investigator |
| P2B001 (DHALL, ROHIT)Aug 16, 2018 Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc. Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. Role: Principal Investigator |
| TOZ-CL06 (DHALL, ROHIT)Aug 8, 2017 Biotie Therapies Inc. A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” Role: Principal Investigator |
| RVT-102-2003 (DHALL, ROHIT)Jul 28, 2017 Axovant Sciences, Ltd. An open-label study of nelotanserin in patients with Lewy body dementia who have frequent visual hallucinations or REM sleep behaviors Role: Principal Investigator |
| M15 (VAN RHEE, FRITS)May 30, 2017 AbbVie Inc A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomiib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Role: Principal Investigator |
| RVT (DHALL, ROHIT)May 17, 2017 Axovant Sciences, Ltd. a Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) and Parkingson's Disease Dementia (PDD) who have REM Sleep behavior disorder (RBD) Role: Principal Investigator |
| RVT-102-2002 (DHALL, ROHIT)May 17, 2017 Axovant Sciences, Ltd. No FP attached Role: Principal Investigator |
| IPX203-B16 (DHALL, ROHIT)Mar 29, 2017 Impax Laboratories, Inc. A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998 Role: Principal Investigator |
| IPX203-B16-01 (DHALL, ROHIT)Mar 29, 2017 Impax Laboratories, Inc. A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998 Role: Principal Investigator |
Outreach Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Bruno MK, Dhall R, Duquette A, Haq IU, Honig LS, Lamotte G, Mari Z, McFarland NR, Montaser-Kouhsari L, Rodriguez-Porcel F, Shurer J, Siddiqui J, Spears CC, Wills AA, Diaz K, Golbe LI. A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders: A Consensus Statement. Neurol Clin Pract. 2024 Dec; 14(6):e200345. PMID: 39185098.
-
Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, Tatiana Foroud, Anne Hall, Karen S Marder, Ignacio F Mata, Niccolò E Mencacci, Martha A Nance, Michael A Schwarzschild, Tanya Simuni, Susan Bressman, Anne-Marie Wills, Hubert H Fernandez, Irene Litvan, Kelly E Lyons, Holly A Shill, Carlos Singer, Thomas F Tropea, Nora Vanegas Arroyave, Janfreisy Carbonell, Rossy Cruz Vicioso, Linn Katus, Joseph F Quinn, Priscila D Hodges, Yan Meng, Samuel P Strom, Cornelis Blauwendraat, Katja Lohmann, Cynthia Casaceli, Shilpa C Rao, Kamalini Ghosh Galvelis, Anna Naito, James C Beck, Roy N Alcalay, on behalf of the Parkinson’s Foundation and Parkinson Study Group PD GENEration investigators. Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024; 147(8):2668–2679.
-
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024 May; 23(5):465-476. PMID: 38499015.
-
McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024 01; 23(1):37-45. PMID: 38101901.
-
Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, Banisadr G, Fisher S, Visser H. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study. Mov Disord. 2024 Feb; 39(2):428-432. PMID: 38111267.
-
Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease. Mov Disord. 2024 Feb; 39(2):350-359. PMID: 37886872.
-
Elberson B, Scott H, Dhall R, Petersen E. Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation: illustrative case. J Neurosurg Case Lessons. 2023 Sep 18; 6(12). PMID: 37756484.
-
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 06; 22(6):494-504. PMID: 37210099.
-
LeWitt P, Ellenbogen A, Burdick D, Gunzler S, Gil R, Dhall R, Banisadr G, D'Souza R. Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clin Park Relat Disord. 2023; 8:100197. PMID: 37181100.
-
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs. 2022 11; 36(11):1207-1216. PMID: 36242718.
-
Ojukwu DI, Wang AR, Hornbeck TS, Lim EA, Sharrard J, Dhall R, Buch VP, Halpern CH. Conversion to Hybrid Deep Brain Stimulation System to Enable Multi-Contact Fractionation Can be Therapeutic. Mov Disord. 2022 06; 37(6):1321-1323. PMID: 35393689.
-
Pfeifer KJ, Cook AJ, Yankulova JK, Mortimer BJP, Erickson-DiRenzo E, Dhall R, Montaser-Kouhsari L, Tass PA. Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol. Front Neurol. 2021; 12:758481. PMID: 34867742.
-
Glover A, Pillai L, Dhall R, Virmani T. Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease. Front Neurol. 2021; 12:656379. PMID: 34456839.
-
Bluett B, Pantelyat AY, Litvan I, Ali F, Apetauerova D, Bega D, Bloom L, Bower J, Boxer AL, Dale ML, Dhall R, Duquette A, Fernandez HH, Fleisher JE, Grossman M, Howell M, Kerwin DR, Leegwater-Kim J, Lepage C, Ljubenkov PA, Mancini M, McFarland NR, Moretti P, Myrick E, Patel P, Plummer LS, Rodriguez-Porcel F, Rojas J, Sidiropoulos C, Sklerov M, Sokol LL, Tuite PJ, VandeVrede L, Wilhelm J, Wills AA, Xie T, Golbe LI. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Front Neurol. 2021; 12:694872. PMID: 34276544.
-
Zavala B, Mirzadeh Z, Chen T, Lambert M, Chapple KM, Dhall R, Ponce FA. Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging. World Neurosurg. 2021 08; 152:e51-e61. PMID: 33905908.
-
Pfeifer KJ, Kromer JA, Cook AJ, Hornbeck T, Lim EA, Mortimer BJP, Fogarty AS, Han SS, Dhall R, Halpern CH, Tass PA. Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease. Front Physiol. 2021; 12:624317. PMID: 33889086.
-
Virmani T, Glover A, Pillai L, Lotia M, Dhall R. Utility of objective gait measures in levodopa-unresponsive freezing in Parkinson's. Clin Case Rep. 2021 Mar; 9(3):1072-1077. PMID: 33768785.
-
Isaacson SH, Peckham E, Tse W, Waln O, Way C, Petrossian MT, Dahodwala N, Soileau MJ, Lew M, Dietiker C, Luthra N, Agarwal P, Dhall R, Morgan J, Calakos N, Zesiewicz TA, Shamim EA, Kumar R, LeWitt P, Shill HA, Simmons A, Pagan FL, Khemani P, Tate J, Maddux B, Luo L, Ondo W, Hallett M, Rajagopal A, Chidester P, Rosenbluth KH, Delp SL, Pahwa R. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2020 08 14; 10:29. PMID: 32864188.
-
Sharma P, Sharma SR, Dhall RK, Mittal TC. Effect of ?-radiation on post-harvest storage life and quality of onion bulb under ambient condition. J Food Sci Technol. 2020 Jul; 57(7):2534-2544. PMID: 32549604.
-
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10. PMID: 31927343.
-
Mirzadeh Z, Chen T, Chapple KM, Lambert M, Karis JP, Dhall R, Ponce FA. Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery. Oper Neurosurg (Hagerstown). 2019 07 01; 17(1):70-78. PMID: 30339204.
-
Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S. An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. Neuromodulation. 2019 Jul; 22(5):537-545. PMID: 30701655.
-
Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic. J Parkinsons Dis. 2019; 9(1):207-219. PMID: 30412506.
-
Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018; 2018:9763057. PMID: 30425824.
-
Chen T, Mirzadeh Z, Chapple KM, Lambert M, Shill HA, Moguel-Cobos G, Tr?ster AI, Dhall R, Ponce FA. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2018 03 16; 130(1):109-120. PMID: 29547091.
-
Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, Dhillon R, Frames CW, McCauley M. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb; 128(2):151-154. PMID: 28911255.
-
Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, P?rez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794. PMID: 28972194.
-
Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161. PMID: 28814455.
-
Ho AL, Ali R, Connolly ID, Henderson JM, Dhall R, Stein SC, Halpern CH. Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):687-691. PMID: 28250028.
-
Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017 Feb; 7(1):86-93. PMID: 28243505.
-
Hauser RA, Li R, P?rez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127. PMID: 27911341.
-
Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50. PMID: 27380342.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24. PMID: 27044646.
-
Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8. PMID: 26886406.
-
Chen T, Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. "Asleep" deep brain stimulation for essential tremor. J Neurosurg. 2016 Jun; 124(6):1842-9. PMID: 26613177.
-
Mirzadeh Z, Chapple K, Lambert M, Evidente VG, Mahant P, Ospina MC, Samanta J, Moguel-Cobos G, Salins N, Lieberman A, Tr?ster AI, Dhall R, Ponce FA. Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. J Neurosurg. 2016 Apr; 124(4):902-7. PMID: 26452116.
-
Augustine EF, P?rez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002. PMID: 26171861.
-
Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378. PMID: 28393083.
-
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803. PMID: 26116315.
-
Pan D, Dhall R, Lieberman A, Petitti DB. A mobile cloud-based Parkinson's disease assessment system for home-based monitoring. JMIR Mhealth Uhealth. 2015 Mar 26; 3(1):e29. PMID: 25830687.
-
Lieberman A, Deep A, Dhall R, Tran A, Liu MJ. Early Freezing of Gait: Atypical versus Typical Parkinson Disorders. Parkinsons Dis. 2015; 2015:951645. PMID: 25785228.
-
Fang JY, P?rez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9. PMID: 25541182.
-
Umeh CC, P?rez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
-
Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. Validation of CT-MRI fusion for intraoperative assessment of stereotactic accuracy in DBS surgery. Mov Disord. 2014 Dec; 29(14):1788-95. PMID: 25377213.
-
Lieberman A, Dhall R, Salins N, Sadreddin A, Moguel-Cobos G, Karis J, Krishnamurthi N. Finger displacement in Parkinson disease: up? down? sideways? Int J Neurosci. 2014 May; 124(5):339-43. PMID: 24053160.
-
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08; 383(9916):533-40. PMID: 24183563.
-
Lieberman A, Dhall R, Dhanani S, Salins N, Sadreddin A, Moguel-Cobos G, Pan D, Santiago A, Prigatano G, Krishnamurthi N, Troster A. Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement. Int J Neurosci. 2014 Mar; 124(3):175-80. PMID: 23879402.
-
Elm JJ. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21. PMID: 23079770.
-
Lieberman A, Krishnamurthi N, Dhall R, Santiago A, Moguel-Cobos G, Sadreddin A, Husain S, Salins N, Pan D. A simple question about falls to distinguish balance and gait difficulties in Parkinson's disease. Int J Neurosci. 2012 Dec; 122(12):710-5. PMID: 22784291.
-
Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 Sep; 38(3):1101-7. PMID: 18720508.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2008 | 1 | 2012 | 2 | 2013 | 3 | 2014 | 3 | 2015 | 7 | 2016 | 3 | 2017 | 6 | 2018 | 2 | 2019 | 4 | 2020 | 2 | 2021 | 6 | 2022 | 2 | 2023 | 5 | 2024 | 4 |
To return to the timeline, click here.
|
Dhall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|